Tradestie Institutional Equity Comparison Engine

SRZN vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
SRZN N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs -62.7%
Momentum & Technical Winner SRZN
1Y +131.0% vs -73.8% ยท 52W Pos 69% vs 14%
Options & Structure Winner SRZN
CONSOLIDATION (5th %ile IV) vs BREAKDOWN (N/A IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.98
-7.24% 1D
Market Cap $602.5M
1M Return +25.76%
1Y Return +130.97%
Forward P/E N/M
Unified AI Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap $22.5M
1M Return +12.12%
1Y Return -73.76%
Forward P/E 23.0x
Unified AI Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +130.97% CVM -73.76% Spread: +203.02 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue CVM Revenue SRZN Op. Margin CVM Op. Margin Margin Edge
FY2011 N/A $0M N/A -1881.0% CVM
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2022 $10M N/A -354.7% N/A SRZN
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M N/A -1210.6% N/A SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (5) vs CVM (4)
Institutional Metric SRZN CVM Criterion Row Winner
Market Capitalization Scale $602.5M $22.5M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY) Growth +408.6% -62.7% Higher Growth SRZN
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin CVM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -252.5% Higher ROE SRZN
52-Week Range Position Momentum 69% ($12โ€“$38) 14% ($1โ€“$8) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.29ฮฒ ยท 67% Vol 0.42ฮฒ ยท 140% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 33.2 / 100 (SELL) 43.5 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs CVM Buy Guide
SRZN CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.